MediLink Therapeutics (Suzhou)
Pre-Approval PRO BETAPipeline by Phase
Therapeutic Focus
Clinical Trials (21)
A Phase III Study of YL201 in Relapsed Small Cell Lung Cancer
Started: 12/17/2024
A Phase III Study of YL201 in Recurrent or Metastatic Nasopharyngeal Carcinoma
Started: 12/31/2024
A Study of YL201 Versus Investigator's Choice of Chemotherapy in Participants With Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Failure of First-Line Therapy
Started: 4/30/2026
YL202 Versus Treatment of Physician's Choice in Patients With HR+/HER2- Breast Cancer
Started: 3/10/2026
Pivotal Study to Evaluate YL202 Versus Docetaxel in Patients With Locally Advanced or Metastatic EGFR Sensitive Mutation Non-Squamous Non-Small Cell Lung Cancer
Started: 3/6/2026
A Study of YL202 in Patients With Advanced Solid Tumors
Started: 8/4/2025
A Study of YL202 in Selected Patients With Advanced Solid Tumors
Started: 12/15/2023
A Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Patients With mCRPC
Started: 2/22/2024
A Phase 2 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of YL202 in Patients With BC
Started: 4/23/2024
A Study of YL201 in Combination With Other Anti-Cancer Therapies in Patients With Advanced Solid Tumors
Started: 3/31/2026
A First-in-Human Study of YL217 in Patients With Advanced Solid Tumors
Started: 7/2/2025
A Phase I Study to Evaluate the Safety,Tolerability, Pharmacokinetics, and Efficacy of YL211 in Patients With Advanced Solid Tumors
Started: 5/1/2024
A Study of YL242 in Subjects With Advanced Solid Tumors
Started: 9/22/2025
A Clinical Study of YL205 in Patients With Advanced Solid Tumors
Started: 6/4/2024
A Study of YL201 in Combination With Toripalimab and With or Without Cisplatin in Nasopharyngeal Carcinoma.
Started: 11/5/2025
A Study of YL201 and Ivonescimab (AK112) in Advanced Solid Tumors
Started: 10/29/2025
A Study of YL201 in Patients With Advanced Solid Tumors
Started: 5/25/2022
A Study of YL202 in Combination With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors
Started: 9/2/2025
A Phase 1 Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Advanced Solid Tumors
Started: 4/17/2024
A Study YL201 in Patients With Selected Advanced Solid Tumors
Started: 9/22/2023
A Study of YL202 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer and Breast Cancer
Started: 12/20/2022